Cannell & Spears’s BioNTech BNTX Stock Holding History

Cannell & Spears’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,000	Closed	-$356K	–	449
2026 Q1	$356K	Hold	4,000	–	–	0.01%	339
2025 Q4	$381K	Hold	4,000	–	–	0.01%	324
2025 Q3	$394K	Hold	4,000	–	–	0.01%	311
2025 Q2	$426K	Hold	4,000	–	–	0.01%	299
2025 Q1	$364K	Hold	4,000	–	–	0.01%	312
2024 Q4	$456K	Hold	4,000	–	–	0.01%	294
2024 Q3	$475K	Buy	+4,000	New	+$368K	0.01%	301

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Cannell & Spears's BNTX Position: Q2 2026 in Review

Cannell & Spears sold out of BioNTech (BNTX) in Q2 2026, closing a stake of 4,000 shares — an estimated $356K sold.

Cannell & Spears first reported a position in BNTX in Q3 2024 and held it in 7 quarters. The position peaked at $475K in Q3 2024. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Cannell & Spears reported no remaining BioNTech position as of Q2 2026 after selling out during the quarter.
Cannell & Spears sold 4,000 BioNTech shares in Q2 2026, an estimated $356K.
Cannell & Spears first reported a position in BioNTech in Q3 2024 and held it in 7 quarters.
Cannell & Spears's BioNTech position peaked at $475K in Q3 2024.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Cannell & Spears's 13F filing for Q2 2026, filed 11 Aug 2026.